Skip to content

Anti-Wrinkle Efficacy Study of an Eye-Cream

Anti-Wrinkle Efficacy Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05805735
Enrollment
36
Registered
2023-04-10
Start date
2023-03-28
Completion date
2023-08-31
Last updated
2023-09-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aging, Wrinkle

Brief summary

The purpose of this study is to assess the anti-aging and reduction of dark circles efficacy of a cosmetic product after 8 weeks of application.

Interventions

OTHERFace care product (Eye cream)

The test material(s) will be cosmetic products to be applied around the eye region on both sides of the face daily. The test product will be applied twice daily in the morning and in the evening by the subjects

Sponsors

proDERM GmbH
CollaboratorINDUSTRY
Amazentis SA
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Masking description

Blinding of sponsor label (de-branded product)

Intervention model description

Intra-individual comparison

Eligibility

Sex/Gender
ALL
Age
40 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Written informed consent to participate in the study * Willingness to actively participate in the study and to come to the scheduled visits * Female and male (approx. 10% male) * Between 40 and 65 years of age * Visible wrinkles in the periorbital regions in accordance with the study site's score of at least grade 3 * Dark circles according to self-assessment (not guaranteed on darker skin types) * Healthy skin in the test areas * Uniform skin color and no erythema or dark pigmentation (except dark cycles are still visible) in the test area

Exclusion criteria

* Female subjects: Pregnancy or lactation * Drug addicts, alcoholics * AIDS, HIV-positive or infectious hepatitis * Conditions which exclude a participation or might influence the test reaction/evaluation * Participation or being in the waiting period after participation in cosmetic and/or pharmaceutical studies pertaining to the test area * Cancer not being diagnosed as cured and requiring chemotherapy, irradiation and/or hormonal treatment within the last 2 years * One of the following illnesses with reduced physical capability/fitness: asthma (symptom-free allergic asthma is not an exclusion criterion), hypertension (if not adjusted with medication), cardiovascular diseases * Insulin-dependent diabetes mellitus * Any topical medication at the test area within the last 7 days prior to the start of the study and/or throughout the entire course of the study * Documented allergies to face care or cleansing products * Active skin disease at the test area * Wounds, moles, tattoos, scars, irritated skin, excessive hair growth, etc. at the test area that could influence the investigation * Past cosmetic surgery procedure in the test area (e.g. laser, facelift) * Cosmetic surgery procedure in the test area, e.g. IPL (Intensed Pulsed Light), botox, chemical peel, dermabrasion within the last 2 years prior to the start of the study * Epilepsy * Obesity with a BMI \> 40 * Systemic therapy with immuno-suppressive drugs (e.g. corticosteroids) and/or antihistamines (e.g. antiallergics) and/or within the last 7 days prior to the start of the study * Medical treatment for wrinkle reduction (e.g. peeling with vitamin A or fruit acids) on the face within the last 2 weeks prior to the start of the study

Design outcomes

Primary

MeasureTime frame
Anti-wrinkle efficacy will be assessed in the periorbital regions wrinkles using DermaTOP. Parameters measured: Rz and Ra, representing mainly the rough structure (Rz) or the finer skin structure (Ra).8-weeks

Secondary

MeasureTime frame
Change from baseline in skin elasticity by Cutometer after 2, 4 and 8 weeks8-weeks
Change from baseline in skin hydration (assessed on skin capacitance by Corneometer [a.u.]) after 2, 4 and 8 weeks8-weeks
Change from baseline in skin barrier function (assessed on transepidermal waterloss by Tewameter [g/(m²h)]) after 2, 4, 8-weeks8-weeks
Dark circles color in difference by ColorFace image analysis Clinical assessment of dark circle reduction around the eye area by trained grader8-weeks
Change from baseline in skin firmness by Cutometer [mm] after 2, 4 and 8 weeks8-weeks
Subjective Evaluation of product traits assessed via questionnaire after 2, 4 and 8 weeks8-weeks
Assessment of eye area puffiness by photo ranking by 3 trained graders8-weeks
Photo documentation of skin by ColorFace8-weeks
Clinical assessment of dark circle reduction by trained grader8-weeks

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026